ENSACOVE Drug Patent Profile

Which patents cover Ensacove, and when can generic versions of Ensacove launch?

Ensacove is a drug marketed by Xcovery and is included in one NDA. There are four patents protecting this drug.

This drug has sixty-seven patent family members in twenty-one countries.

The generic ingredient in ENSACOVE is ensartinib hydrochloride. One supplier is listed for this compound. Additional details are available on the ensartinib hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ensacove

Ensacove will be eligible for patent challenges on December 18, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ENSACOVE

International Patents:	67
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ENSACOVE?	ENSACOVE excipients list
DailyMed Link:	ENSACOVE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ENSACOVE

Constraining patent/regulatory exclusivity:

9,126,947

NDA:

218171

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ENSACOVE

ENSACOVE is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 9,126,947.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-001	Dec 18, 2024		RX	Yes	No	10,899,744			Y
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-002	Dec 18, 2024		RX	Yes	Yes	9,296,724			Y
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-001	Dec 18, 2024		RX	Yes	No	9,126,947			Y
Xcovery	ENSACOVE	ensartinib hydrochloride	CAPSULE;ORAL	218171-002	Dec 18, 2024		RX	Yes	Yes	9,126,947			Y

International Patents for ENSACOVE

When does loss-of-exclusivity occur for ENSACOVE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Japan

Poland

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ENSACOVE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017274110
Brazil	112018074612
Canada	3026142
China	109195964

Last updated: June 25, 2026

EnsaCove market dynamics and financial trajectory: revenue drivers, pricing, access, and exclusivity risks

EnsaCove (ensitrelvir) has a short, high-uncertainty financial arc because commercial traction depends on: (1) country-by-country adoption of ensitrelvir for acute viral indications, (2) payer reimbursement and hospital formulary placement, and (3) the strength and timing of IP and regulatory barriers that delay first generic and biosimilar-like competitive entries. No enforceable financial trajectory (revenue, forecasts, launch-by-launch sales, or profit contribution) can be stated from the provided information.

This market-dynamics and IP-risk brief is the actionable baseline for investors, licensors, and litigators:

• Key commercial variables: tender volumes, treatment-course pricing, uptake of oral outpatient vs inpatient pathways, and distribution channel readiness.
• Key downside variables: payer restrictions, formulary exclusion, and faster-than-expected launch of copy products or follow-on products.
• Key upside variables: guideline inclusion, public health purchasing scale, and channel contracting that converts forecasted demand into booked orders.

---

What is EnsaCove’s commercial positioning and who is driving uptake?

EnsaCove’s uptake is determined by the decision chain for acute viral treatment, which in most markets runs through hospital pharmacy leadership for inpatient use and through payer coverage plus outpatient prescriber preferences for ambulatory use.

Which payer and provider segments matter most

• National or regional tenders (public procurement): drive bulk volume, compress net pricing through procurement leverage, and often shift growth from retail to tender-led forecasting.
• Hospital formularies: determine whether EnsaCove is stocked for emergency and acute care pathways.
• Outpatient reimbursement: determines whether prescribers can write repeatable prescriptions without patient cost barriers.

What tends to accelerate adoption

• Clear place-in-therapy relative to competing oral antivirals.
• Evidence-backed safety/tolerability that reduces monitoring cost.
• Stable supply and contracting that ensures course availability without stockouts.

What tends to slow adoption

• Prior authorization requirements and narrow reimbursement criteria.
• Limited clinician confidence in real-world effectiveness in the presence of resistance.
• Operational bottlenecks (cold-chain typically matters less for small molecules, but distribution and allocation controls can still create delays).

---

How do pricing and reimbursement dynamics shape EnsaCove net revenue?

Net revenue for EnsaCove will be dominated by the gap between launch list price and realized net price after discounts, tender rebates, and payer concessions.

Pricing architecture that typically governs net price

• Tender-led net pricing: procurement usually yields large volume but materially lower net price per course.
• Private pay and insured retail: tends to preserve list price but can cap volume if patient cost sharing remains high.
• Specialty channel contracting: if EnsaCove is managed through specialty distributors, net price depends on channel margins and performance rebates.

Reimbursement constraints to monitor

• Restriction to specific severity tiers or time-from-symptom windows.
• Coverage that depends on testing outcomes.
• Geographic differences in reimbursement status and formulary tiering.

---

What does the sales funnel look like after launch for EnsaCove?

For short-horizon antiviral launches, the sales funnel is typically:

1. Regulatory approval and guideline uptake (enables prescribing)
2. Hospital stocking and tender awards (enables dispensing)
3. Payer reimbursement and patient access (converts prescriptions into paid volume)
4. Repeatable prescribing behavior (drives staying power)

Key leading indicators

• Tender award counts and awarded volume shares.
• Hospital formulary addition and number of stocked sites.
• Prescription and dispensing volume proxies (where tracked).
• Allocation and backorder status that affects realized volumes.

Key lagging indicators

• Net revenue per course after rebate and discount schedules.
• Effective gross-to-net bridge (discount rates, chargebacks).
• Market share drift once competing alternatives enter.

---

When does EnsaCove face exclusivity erosion, and what does it change financially?

Financial trajectory changes materially at exclusivity step-down points because market structure shifts from protected monopoly pricing to competitive pricing pressure.

Exclusivity erosion pathways that typically matter

• Patent term expiration for active ingredient and key compositions.
• Second-wave protection (formulation, dosing regimens, manufacturing method patents) that can extend exclusivity for specific product variants.
• Regulatory exclusivity periods where applicable, which can delay approval even when patents expire.

What to expect after exclusivity loss

• Net price compression as copy products or authorized generics enter.
• Margin compression as wholesalers and payers rebid contract terms.
• Volume volatility as prescribers switch quickly once barriers fall.

---

What patents protect ensitrelvir/EnsaCove, and how strong is the patent estate?

A structured patent strength assessment is not possible from the information provided. A defensible analysis requires a list of the specific ensitrelvir patents and their jurisdictional status (grant status, remaining term, and claim scope) and the specific FDA Orange Book or equivalent listings.

What the patent estate typically includes for antivirals

• Composition of matter (active ingredient).
• Pharmaceutical compositions (solid forms, excipients, dosage forms).
• Method-of-use claims (treatment regimen, patient subsets, timing).
• Manufacturing and process claims.
• Polymorph/crystal form claims if relevant.

How patent strength ties to revenue trajectory

• Strong estate: supports stable net pricing through delayed generic entry.
• Weak estate: accelerates competitive erosion and forces price concessions earlier.

---

Which companies are challenging EnsaCove with generic or biosimilar applications?

This cannot be determined from the provided information. To assess Paragraph IV risk (or foreign equivalent challenges), you need the listing and status of relevant regulatory filings and litigation captions.

Commercial implication of a challenge

• A successful challenge can shift market share quickly and reduce realized pricing.
• A withdrawn or unsuccessful challenge can preserve market protection longer than forecast.

---

What is the Orange Book status of EnsaCove and its exclusivity listings?

No Orange Book listing content is included in the provided information, so the status of:

• active ingredient,
• dosage form,
• exclusivity periods,
• and listed patents
  cannot be stated.

Why Orange Book data matters for the financial trajectory

• Orange Book entries and listed expiration dates create the “time-to-generic” schedule.
• Exclusivity and patent listing patterns often explain why revenue holds after launch and how quickly it erodes later.

---

What patent litigation affects EnsaCove, and how do settlements change timelines?

This cannot be stated from the provided information. Settlement agreements and court rulings are often the determinant of whether generic entry happens at the first legally permitted window or later under agreed covenants.

How litigation outcomes translate into financial timing

• Early favorable outcomes for the innovator: sustained higher net pricing and slower volume loss.
• Settlements granting “design-around” or delayed entry: predictable erosion and modeled revenue decline curves.
• Adverse outcomes or narrow injunctions: faster competitive switching and steeper net price compression.

---

How does EnsaCove compare with competing antivirals on market adoption and expected revenue pressure?

A comparative market dynamics analysis cannot be completed without competitors, pricing, market share, and channel access data. A defensible comparison depends on:

• approved indication overlap,
• dosing convenience,
• evidence strength,
• formulary status,
• and local tender awards.

Comparison axes that drive financial outcomes

• Time-from-symptom window and testing workflow fit.
• Safety profile and monitoring requirements.
• Total treatment cost to payers, not list price alone.

---

What manufacturing and supply risks could change EnsaCove revenue in the near term?

No EnsaCove-specific supply chain details are provided, so this section cannot be filled with firm, product-specific barriers.

What typically moves revenue in antivirals

• Allocation rules at launch.
• Contract manufacturing capacity lead times.
• Stability and packaging line availability that affects course availability.

---

Key Takeaways

• EnsaCove’s financial trajectory is driven by adoption and realized net price, which depend on tender awards, formulary access, and payer reimbursement.
• Revenue erosion timing is governed by exclusivity and patent barriers, but those details cannot be established from the provided information.
• Generic-entry and litigation outcomes determine the shape of the decline curve, yet the relevant challenges and cases are not provided.
• Supply constraints and allocation can materially distort early realized sales if demand outpaces capacity.

---

FAQs

1. How quickly do oral antivirals lose market share after first generic entry?
2. What role do hospital tenders play in determining net price versus retail pricing for antiviral drugs?
3. How do method-of-use and formulation patents affect the timing of competitive switches in protected products?
4. What indicators best predict whether payers will broaden or restrict reimbursement for an antiviral after launch?
5. How do settlements between innovator and generic companies change expected entry dates and revenue forecasts?

---

References

No sources were provided in the prompt, and no external documents were cited.